J Cancer 2020; 11(21):6243-6247. doi:10.7150/jca.47065 This issue

Research Paper

Cancer patients in SARS-CoV-2 infection: a single-center experience from Wuhan

Jiafeng Wang1,2*, Jun Zhang2,3*, Yuexing Tu2,3, Xianlong Zhou4,5, Haijun Huang2,3, Lina Shao2,3, Legao Chen2,3, Yan Zhao4,5✉, Minghua Ge2,3✉

1. The 2nd Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China.
2. Medical Aiding Team for COVID-19 in Hubei, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, 310014, China.
3. Hangzhou Medical School People's Hospital, Hangzhou, Zhejiang, 310014, China.
4. Emergency Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China.
5. Hubei Clinical Research Center for Emergency and Resuscitation, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China.
*These authors contributed equally to this article.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Wang J, Zhang J, Tu Y, Zhou X, Huang H, Shao L, Chen L, Zhao Y, Ge M. Cancer patients in SARS-CoV-2 infection: a single-center experience from Wuhan. J Cancer 2020; 11(21):6243-6247. doi:10.7150/jca.47065. Available from https://www.jcancer.org/v11p6243.htm

File import instruction

Abstract

Background: The Coronavirus disease 2019 (COVID-19) global pandemic has posed unprecedented challenges to the health-care systems all over the world. Among the booming literatures about COVID-19, there is yet a paucity of study addressing the association between COVID-19 and cancer, which is a rare comorbidity of COVID-19, as well as consensus for treatment of cancer in this pandemic.

Methods: In this retrospective, single-center cohort study, information of all inpatient cases with laboratory-confirmed COVID-19 who had treatment outcome were collected from the designated departments in Zhongnan Hospital of Wuhan University, Wuhan, China on March 10, 2020. Demographic data, clinical information, and treatment outcomes were extracted from electronic medical records. Severe events were defined as admission to intensive care unit (ICU), the use of mechanical ventilation, or death.

Result: A total of 716 patients with laboratory-confirmed COVID-19 infection were identified. Among them, a total of 12 cases (1.7%, 95% CI: 0.7%-2.6%) had history of cancer with 4 cases (33%) experienced severe events. Compared with cases without cancer, patients with cancer have higher risks of severe events (33% vs 7.7%, p=0.012) and deaths (25% vs 3.6%, p=0.009). Multivariable logistic regression model showed that cancer was independently associated with increased odds of severe events after adjusting for other risk factors (OR 6.51, 95% CI 1.72-24.64; p=0.006). Among COVID-19 patients with cancer, we found that patients older than 60 years (75%), with other comorbidities (50%), or experiencing anticancer treatment in past month (42.9%) had a numerically higher incidence of severe events.

Conclusion: Cancer is a rare comorbidity of patients with COVID-19; however, it cannot be overemphasized due to its poorer outcomes. We propose that personalized treatment recommendation for cancer patients should be addressed during COVID-19 pandemic, along with meticulous personal protective protocols for them to mitigate the risk of SARS-CoV-2 infection.

Keywords: COVID-19, Coronavirus, Pandemic, Cancer, Therapy